A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Opicapone (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Neurocrine Biosciences
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 20 Sep 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 20 Sep 2018 Status changed from recruiting to active, no longer recruiting.